NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
NeoGenomics Reports Second Quarter 2026 Results
NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS